Compass Therapeutics, Inc. (CMPX)
(Delayed Data from NSDQ)
$0.90 USD
-0.06 (-6.52%)
Updated Aug 7, 2024 03:59 PM ET
After-Market: $0.90 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Compass Therapeutics, Inc. [CMPX]
Reports for Purchase
Showing records 1 - 20 ( 76 total )
Company: Compass Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1 Study Results at ASCO Showcase Potential of CTX-471 as Monotherapy Treatment in Advanced Solid Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Compass Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology -ASCO 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Compass Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Doc Survey Highlights Deep Need in Advanced CRC; We Believe CTX-009 Can Raise the Bar
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Compass Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Pipeline Continues to Advance; Top-Line CRC Phase 2 Results On Track for Mid-24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Compass Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; COMPANION-003 CRC Data Update on Track for mid:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Compass Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- ASCO 2024 Abstract Titles for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Compass Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1 CTX-8371 Trial Begins With Important Clinical Pipeline Expansion; Key ''009 Results Upcoming
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Compass Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CTX-009 and CTX-471 Combo Therapy at AACR Suggests New Opportunities for Pipeline Growth
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Compass Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Compass Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; All Eyes on Key Data Updates For CTX-009; Top-line CRC Phase 2 Results Expected By Mid-24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Compass Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23 Financials; An Exciting Time for CTX-009
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Compass Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Compass Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Compass Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Guiding for 2024: CTX-009 Clinical Data Ahead; CTX-471 Positive Updates
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Compass Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Important Pipeline Updates to Come; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Compass Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Oncology Portfolio Stays the Course With Multiple Clinical Updates in 4Q23 and 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Compass Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Compass Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Compass Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; CTX-009 CRC Data in 2H:23, BTC Combo Data Delayed to 2H:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R